Pradaxa 110 mg hard capsules

${arrow_up}$ Back to top

Active Ingredient:

dabigatran etexilate mesilate

Company:

Boehringer Ingelheim Limited See contact details

ATC code:

B01AE07

About Medicine

${medical_services}$

Prescription only medicine

My Account Area

${arrow_down}$

Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Safety Alert HCP Med Info

${arrow_left}$

${arrow_right}$

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

${pdf_link}$

Pradaxa (dabigatran etexilate) Prescriber guide for primary prevention of venous thromboembolic events (VTE) following elective hip or knee replacement surgery

This risk minimisation material provides recommendations for the use of Pradaxa in VTE (orthopaedic) in order to minimise the risk of bleeding. Please ensure you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

${pdf_link}$

Pradaxa (dabigatran etexilate) Prescriber Guide for stroke prevention in non-valvular atrial fibrillation (NVAF) and for the treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)

This risk minimisation material provides recommendations for the use of Pradaxa in NVAF and DVT/PE in order to minimise the risk of bleeding. Please ensure that you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

${pdf_link}$

Pradaxa (dabigatran etexilate) Prescriber guide for paediatric use for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age (paed. VTE)

This risk minimisation material provides recommendations for the use of Pradaxa for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age (paed. VTE) in order to minimise the risk of bleeding. Please ensure you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa in the paediatric population and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

${pdf_link}$

Pradaxa (dabigatran etexilate) Patient Alert Card

Every patient prescribed Pradaxa will receive a Patient Alert Card in the medication pack. As the card contains important information the patient should be instructed to carry the patient alert card at all times and present it when seeing a health care professional. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.

Address

Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS

WWW

http://www.boehringer-ingelheim.co.uk

Telephone

+44 (0)1344 424 600

Fax

01344 741444

Medical Information Direct Line

+44 (0)1344 742579 - Pradaxa enquiries

Medical Information e-mail

[email protected]

My Account Area

Report side effect